TY - JOUR
T1 - Cytoplasmic p53 Immunostaining in Salivary Duct Carcinoma
T2 - A Poor Prognostic Factor Associated With Characteristic TP53 Variants
AU - Multi-institutional Joint SDC Study Group in Japan
AU - Utsumi, Yoshitaka
AU - Nakaguro, Masato
AU - Kawakita, Daisuke
AU - Hirai, Hideaki
AU - Sukeda, Aoi
AU - Kohsaka, Shinji
AU - Tsukahara, Kiyoaki
AU - Hanazawa, Toyoyuki
AU - Kano, Satoshi
AU - Yamazaki, Keisuke
AU - Ueki, Yushi
AU - Okami, Kenji
AU - Saito, Yuki
AU - Ozawa, Hiroyuki
AU - Honma, Yoshitaka
AU - Shimizu, Akira
AU - Hanyu, Kenji
AU - Fujii, Shota
AU - Arai, Tomoyuki
AU - Iwaki, Sho
AU - Imaizumi, Sae
AU - Tanaka, Ryoko
AU - Yamauchi, Mayu
AU - Yamamura, Koji
AU - Sekimizu, Mariko
AU - Takahashi, Hideaki
AU - Imanishi, Yorihisa
AU - Sato, Yuichiro
AU - Matsuki, Takashi
AU - Tada, Yuichiro
AU - Nagao, Toshitaka
N1 - Publisher Copyright:
© 2025 United States & Canadian Academy of Pathology
PY - 2025/7
Y1 - 2025/7
N2 - Salivary duct carcinoma (SDC) is an uncommon, high-grade malignancy. Identifying suitable prognostic factors is crucial for developing effective treatment strategies for SDC. p53 Immunohistochemistry (IHC) is a potential prognostic marker for SDC. Traditionally, only the nuclear expression has been considered when evaluating aberrant p53 IHC patterns. However, recent studies on other organ cancers have highlighted the significance of the cytoplasmic p53 expression. We aimed to investigate the prognostic implications of cytoplasmic p53 positivity and its association with TP53 variants in a large cohort of patients with SDC. p53 IHC was performed in 327 patients with SDC who had undergone primary curative resection. Based on the immunostaining patterns, patients were classified into 4 groups: wild-type (WT), overexpression (OE), complete absence (CA), and cytoplasmic (CY). Additionally, the TP53 gene status was analyzed in 239 cases by Sanger and/or next-generation sequencing. The p53 IHC patterns of 327 cases were as follows: WT (n = 125; 38.2%), OE (n = 100; 30.6%), CA (n = 75; 22.9%), and CY (n = 27; 8.3%). A TP53 genetic analysis of 239 cases revealed the following: WT status (n = 80; 33.5%), missense/inframe variants (n = 86; 36.0%), and truncating variants (n = 73; 30.5%). Notably, 24 of the 25 CY cases (96%) harbored TP53 variants, which were predominantly located in the domains responsible for nuclear translocation. Of these, 22 exhibited truncating variants. In a multivariate analysis, CY cases demonstrated significantly shorter disease-free survival (DFS) than WT cases (P = .01). Furthermore, patients with aberrant p53 expression patterns (OE+CA+CY) had significantly worse DFS and overall survival than those with WT (P = .003 and .002, respectively). The presence of TP53 variants was also associated with poorer DFS and overall survival (P = .003 and .02, respectively). Our findings suggest that the cytoplasmic expression of p53 in SDC represents a distinct aberrant pattern underlying characteristic genetic abnormalities and has significant prognostic implications.
AB - Salivary duct carcinoma (SDC) is an uncommon, high-grade malignancy. Identifying suitable prognostic factors is crucial for developing effective treatment strategies for SDC. p53 Immunohistochemistry (IHC) is a potential prognostic marker for SDC. Traditionally, only the nuclear expression has been considered when evaluating aberrant p53 IHC patterns. However, recent studies on other organ cancers have highlighted the significance of the cytoplasmic p53 expression. We aimed to investigate the prognostic implications of cytoplasmic p53 positivity and its association with TP53 variants in a large cohort of patients with SDC. p53 IHC was performed in 327 patients with SDC who had undergone primary curative resection. Based on the immunostaining patterns, patients were classified into 4 groups: wild-type (WT), overexpression (OE), complete absence (CA), and cytoplasmic (CY). Additionally, the TP53 gene status was analyzed in 239 cases by Sanger and/or next-generation sequencing. The p53 IHC patterns of 327 cases were as follows: WT (n = 125; 38.2%), OE (n = 100; 30.6%), CA (n = 75; 22.9%), and CY (n = 27; 8.3%). A TP53 genetic analysis of 239 cases revealed the following: WT status (n = 80; 33.5%), missense/inframe variants (n = 86; 36.0%), and truncating variants (n = 73; 30.5%). Notably, 24 of the 25 CY cases (96%) harbored TP53 variants, which were predominantly located in the domains responsible for nuclear translocation. Of these, 22 exhibited truncating variants. In a multivariate analysis, CY cases demonstrated significantly shorter disease-free survival (DFS) than WT cases (P = .01). Furthermore, patients with aberrant p53 expression patterns (OE+CA+CY) had significantly worse DFS and overall survival than those with WT (P = .003 and .002, respectively). The presence of TP53 variants was also associated with poorer DFS and overall survival (P = .003 and .02, respectively). Our findings suggest that the cytoplasmic expression of p53 in SDC represents a distinct aberrant pattern underlying characteristic genetic abnormalities and has significant prognostic implications.
KW - TP53 nuclear localization domain
KW - next-generation sequencing
KW - p53 cytoplasmic pattern
KW - p53 immunohistochemistry
KW - prognostic factor
KW - salivary duct carcinoma
UR - https://www.scopus.com/pages/publications/105003718443
UR - https://www.scopus.com/inward/citedby.url?scp=105003718443&partnerID=8YFLogxK
U2 - 10.1016/j.modpat.2025.100766
DO - 10.1016/j.modpat.2025.100766
M3 - Article
C2 - 40204093
AN - SCOPUS:105003718443
SN - 0893-3952
VL - 38
JO - Modern Pathology
JF - Modern Pathology
IS - 7
M1 - 100766
ER -